Redeye: Transtema - On the Right Track in Sweden
Redeye maintains a positive view of Transtema following a softer Q3 than expected due to weak margins in Norway. We are encouraged about Sweden’s progress and retain our expectations of a solid 2025 – although we somewhat cut our assumptions on Norway.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/